BD COR™ System

Comprehensive capabilities. Breakthrough performance.

Contact Us


Discover the life inside the BD COR™ System

Delivering efficiency, flexibility, and performance to meet your laboratories' evolving molecular diagnostic needs. The BD COR™ System uses multiplex PCR assay design and requires less than 1 hour of daily hands-on time for the full BD COR™ system workflow and only 2 interactions.



  • Fully integrated automation from specimen to result
  • Minimal interaction required to maintain a high level of system throughput
  • Up to 330 sample results on the BD COR™ GX instrument and 1248 sample results on the BD COR™ MX dual instrument configuration when consumables are fully reloaded to get 2 shifts of results with 1 shift of work



  • Modular and scalable to deliver needed throughput and overall system output
  • Remote monitoring with internal cameras and built-in redundancy to maximize uptime
  • Multiplex PCR assay design supports accurate diagnostics



  • Distinct instrument configurations based on your laboratory’s workflow needs through robust laboratory assessments
  • Random and continuous access that requires less than 1 hour of daily hands-on time for the full BD COR™ workflow with only 2 interactions
  • Ability to use different collection types depending on the assay being run – BD SurePath™ Liquid-based Pap Test, Hologic ThinPrep® Pap Test, BD Molecular Swab Collection Kit, and BD Molecular Urine Transport Kit

Related Products


BD COR™ System Products

  • Enhances laboratory operations and patient management with advanced molecular diagnostics capabilities
  • Delivers efficiency, flexibility and performance to meet laboratories evolving molecular diagnostic needs.
  • Provides complete chain of custody and is the only high throughput fully integrated pre-analytical and analytical system on the market.

BD COR™ GX Instrument
The GX Instrument is an HPV analytical instrument that automates the BD Onclarity™ HPV Assay with extended genotyping, requiring minimum interactions per shift at maximum throughput.
Minimal time at the instrument
  • Less than 15 minutes to fully load instrument
  • Remote system management and alert capabilities
  • High capacity for reagents, consumables, samples and system waste


Extended walk-away time and maximum throughput
  • Approximately 7 hours of walk-away time at maximum throughput
  • Up to 180 HPV samples with extended genotyping without user intervention
  • Ready-to-use barcoded reagents stored at room temperature




BD COR™ PX Instrument
The PX Instrument automates preanalytical steps to simplify and standardize workflows, reducing staff interaction and maximizing walk-away time.
Complete pre-analytic automation
  • Automatically converts, vortexes, uncaps, aliquots, and recaps LBC vials
  • Preforms all necessary prewarming and cooling steps
  • Automatically delivers sample to analytical instruments
  • Coordinates sample batching to ensure maximum throughput without user involvement
  • Barcode-drive chain of custody for full traceability and follow-up testing
High storage capacity
  • 480 BD SurePath™ Liquid-based Pap Test Vials
  • 2,140 BD Collection Devices for IVD Assays
  • Reduces hands-on-time, which may reduce the potential for human error





BD COR™ MX Instrument
The MX instrument is a molecular diagnostics analytical instrument for integrated automation of an expanding list of high-demand, essential assays in women’s health and infectious disease testing.
Maximum throughput
  • Dual BD COR™ MX configuration can process 1,872 sample results in less than 24 hours
  • One BD COR™ MX configuration has capacity for 17 different assays and up to 1,000 sample results with one 8-hour shift of work
  • Approximately 7 hours of unimpeded system processing
Minimal system interaction and assay variety
  • Assay reagents do not require reconstitution and are stored at room temperature
  • Less than 15 minutes to fully load consumables
  • Essential assays for sexually transmitted infections, women’s health, and other infectious diseases





Electrical requirements

Voltage100-240 VAC
Frequency50-60 Hz
CurrentSingle-phase circuit 15 A

Operating conditions

Temperature18°C – 27°C / 64.4°F – 80.6°F
Humidity20% to 80%
AltitudeUp to 2,000 m (6,562 ft)
Noise metrics< 67 dB

Specimen handling*

Specimen collection typeBD SurePath™ Liquid-based Pap Test Vials
BD Molecular Aliquot Tubes
BD Onclarity™ HPV Liquid-based Cytology (LBC) Specimen
Diluent Tubes
ThinPrep® PreservCyt® Solution
Reagent/consumable capacityBD COR™ GX Instrument: 180 HPV tests; 1,056 tips (11 tip trays)
BD COR™ PX Instrument: 35 racks; 192 tips (2 trays; buffer)
Waste capacitySolid: 960 conversions (24 hours)
Liquid: 2,160 tests (3 days)


*Capacity and throughput may vary based on specimen types.


BD COR™ System Assays

The BD COR™ System automates the BD women’s health assays that were designed to address real clinical unmet needs. The range of Women’s Health assays has been designed over years, with robust research and development efforts and with demonstrated clinical precision. Learn more about BD Women’s Health Assays on BD Women's Health


BD Onclarity™ HPV Assay

The BD Onclarity™ HPV Assay is the only FDA and Health Canada- approved assay with extended genotyping out of either the BD SurePath™ Liquid-based Pap Test or the Hologic ThinPrep® Pap Test, positioning your laboratory at the forefront of cervical cancer screening, by enabling you to provide more actionable information to clinicians.


Find out more about how BD Onclarity™ HPV Assay is shaping the future of Women’s Health

BD CTGCTV2 for BD COR™ System

The BD CTGCTV2 assay performed on the BD COR™ System is designed to be used with the BD Molecular specimen collection and transport devices for male and female urine, vaginal, endocervical swabs, and liquid based cytology specimens (Thinprep® PreservCyt® Solution). The assay is also indicated for use with asymptomatic and symptomatic individuals to aid in the diagnosis of chlamydial urogenital disease, gonococcal urogenital disease and/or trichomoniasis.


Learn more about the BD CTGCTV2 assay and how it is shaping the future of women’s health